SCHEMBL2086845

SCHEMBL2086845

CC(C)(C)OC(=O)NC1=NC(c2ccc(O[Si](C)(C)C(C)(C)C)cc2)(c2cccc(Br)c2)c2ccccc21

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.35
BACE1 P56817 5/20 0.34
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
EGFR P00533 1/20 0.31
RAF1 P04049 1/20 0.31
KDR P35968 1/20 0.31
MAP2K2 P36507 1/20 0.31
MAP2K1 Q02750 1/20 0.31
AURKB Q96GD4 1/20 0.31
CTSD P07339 1/20 0.30
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30
CTSB P07858 1/20 0.30
CTSS P25774 1/20 0.30
CTSK P43235 1/20 0.30
USP30 Q70CQ3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2085499 0.88 BACE1 (0.36) PDK2BACE1HCRTR1HCRTR2EGFR
SCHEMBL2086137 0.87 PDK2 (0.34) PDK2BACE1EGFRRAF1KDR
SCHEMBL2085888 0.79 BACE1 (0.43) BACE1CTSD
SCHEMBL2086227 0.79 DHFR (0.34) PDK2BACE1RAF1CTSDHSP90AA1
SCHEMBL2084763 0.78 MIF (0.37) PDK2BACE1HSP90AA1HSP90AB1
SCHEMBL2086590 0.77 NPC1 (0.37) PDK2BACE1RAF1CTSDHSP90AA1
SCHEMBL2085194 0.74 HSP90AA1 (0.36) BACE1CTSDHSP90AA1HSP90AB1
SCHEMBL3920247 0.71 BACE1 (0.34) BACE1CTSD
SCHEMBL2086235 0.69 HSP90AA1 (0.38) PDK2BACE1CTSDHSP90AA1HSP90AB1
Acetic Acid SCHEMBL2084828 0.67 BACE1 (0.47) BACE1CTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110059992-A1 New Compounds ASTRAZENECA AB (SE) 2011-03-10 US disclosed
US-20110059992-A1 New Compounds ASTRAZENECA AB (SE) 2011-03-10 US disclosed
US-7855213-B2 Compounds ASTRAZENECA AB (SE) 2010-12-21 US disclosed
US-7855213-B2 Compounds ASTRAZENECA AB (SE) 2010-12-21 US disclosed
EP-2035378-A1 SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE AstraZeneca AB (SE) 2009-03-18 EP disclosed
US-20080171771-A1 New Compounds 391 ASTRAZENECA AB (SE) 2008-07-17 US disclosed
US-20080171771-A1 New Compounds 391 ASTRAZENECA AB (SE) 2008-07-17 US disclosed
WO-2007149033-A1 SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059992-A1 New Compounds MAPT, PSEN2, PSEN1 PDK2 2938/4885BACE1 5/4885HCRTR1 422/4885
US-20080171771-A1 New Compounds 391 PSEN2, PSEN1, MAPT PDK2 2812/4885BACE1 4/4885HCRTR1 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.